Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)

Purpose

Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in addition to standard of care (SOC) for inpatients with COVID-19. The SOC will be determined by local established guidelines and may include additional DAA (e.g., remdesivir) and immunomodulatory treatment strategies. Certain SOC treatments will be pre-specified prior to randomization.

Condition

  • COVID-19

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥18 years. - Informed consent for trial participation. - Hospital admission (or boarding in an emergency department or other area awaiting hospital admission) with signs and/or symptoms of a respiratory infection. - Confirmation of SARS-CoV2 infection by nucleic acid test (NAT) or equivalent non- NAT test [list of approved tests is in the PIM] collected within the prior 14 days. - Onset of symptoms attributable to SARS-CoV2 infection occurred within 14 days before randomization. - Hospitalized for the management of COVID-19, with signs and/or symptoms suggestive of lower respiratory tract infection.

Exclusion Criteria

  • The patient is expected to be discharged from the hospital within the next 24 hours. - Medical condition other than the acute respiratory infection (and its manifestations) that is likely to result in death within 7 days of randomization. - Use of a strong CYP3A inducer within 14 days prior to enrollment - Moribund condition, defined as prior cardiac arrest during this hospitalization and life expectancy less than 48 hours of randomization. - Patient undergoing comfort care measures only such that treatment focuses on end-of- life symptom management over prolongation of life. - Expected inability or unwillingness to participate in study procedures. - In the opinion of the investigator, participation in a trial is not in the best interest of the patient. - Allergy to investigational agent or vehicle - Use of a concomitant medication that is contraindicated due to a drug-drug interaction with S-217622 - Moderate to severe hepatic impairment (i.e., Child-Pugh class B or C) or acute liver failure. - Known estimated glomerular filtration rate (eGRF) <30 mL/min/1.73m 2 - Continuous renal replacement therapy or chronic dialysis - Current pregnancy - Current breastfeeding and unwillingness to defer breastfeeding for 30 days after the last dose of investigational agent. - Women of child-bearing potential who are unwilling to abstain from sexual intercourse with men or practice appropriate contraception through 30 days from the last dose of the investigational agent. - Men who are unwilling to abstain from sexual intercourse with women of child- bearing potential or to use barrier contraception through 30 days from the last dose of the investigational agent. - Inability to take investigational agent in tablet form by mouth.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
S-217622 (ensitrelvir) plus standard of care (SOC)
Study investigational agent (ensitrelvir) will be administered as oral tablets with dosing of 375mg (3 tabs) once on Day 0 and 125mg (1 tab) once daily on Days 1-4. All participants will receive the full 5-day course, including those who are discharged from hospitalization prior to Day 4.
  • Drug: Shionogi Protease Inhibitor (S-217622)
    S-217622 (ensitrelvir) is an oral anti-SARS-CoV2 PI that does not require ritonavir co-administration The dose is 375/125 (375 mg on Day 0, followed by 125 mg daily on Days 1-4).
    Other names:
    • ensitrelvir
Placebo Comparator
placebo plus standard of care (SOC)
Study investigational placebo will be administered as oral tablets with dosing of 375mg (3 tabs) once on Day 0 and 125mg (1 tab) once daily on Days 1-4. All participants will receive the full 5-day course, including those who are discharged from hospitalization prior to Day 4.
  • Drug: placebo
    Placebo is an oral tablet administered once (3 tabs) on Day 0 and once (1 tab) daily on days 1-4, 5-day course.

Recruiting Locations

University of Alabama Birmingham University Hospital (Site 213-002)
Birmingham, Alabama 35233
Contact:
Nashville ICC
strivenash@insight-trials.org

Banner University Medical Center Tucson (Site 206-004)
Tucson, Arizona 85719
Contact:
Nashville ICC
strivenash@insight-trials.org

Southern Arizona VA Healthcare System (Site 074-009)
Tucson, Arizona 85723
Contact:
VA ICC
striveva@insight-trials.org

UCSF Fresno (Site 203-005)
Fresno, California 93721
Contact:
Nashville ICC
strivenash@insight-trials.org

VA Loma Linda Healthcare System (Site 074-017)
Loma Linda, California 92357
Contact:
VA ICC

MemorialCare Health System (Site 066-003
Long Beach, California 90806
Contact:
Washington ICC
strivewdc@insight-trials.org

VA Long Beach Healthcare System (Site 074-026)
Long Beach, California 90822
Contact:
VA ICC
striveva@insight-trials.org

Cedars-Sinai Medical Center (Site 208-002)
Los Angeles, California 90048
Contact:
Nashville ICC
strivenash@insight-trials.org

Ronald Reagan UCLA Medical Center (Site 203-002)
Los Angeles, California 90095
Contact:
Nashville ICC
strivenash@insight-trials.org

VA Northern California Health Care System (Site 074-023)
Mather, California 95655
Contact:
VA ICC
striveva@insight-trials.org

Hoag Memorial Hospital Presbyterian (Site 080-026)
Newport Beach, California 92663
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Veterans Affairs Palo Alto Health Care System (VAPAHCS) (Site 074-005)
Palo Alto, California 94304
Contact:
VA ICC
striveva@insight-trials.org

UC Davis Health (Site 203-004)
Sacramento, California 95817
Contact:
Nashville ICC

VA San Diego Healthcare System (Site 074-016)
San Diego, California 92161
Contact:
VA ICC
striveva@insight-trials.org

Zuckerberg San Francisco General Hospital and Trauma Center (Site 213-007)
San Francisco, California 94110
Contact:
Nashville ICC
strivenash@insight-trials.org

UCSF Medical Center at Mount Zion (203-007)
San Francisco, California 94115
Contact:
Nashville ICC
strivenash@insight-trials.org

San Francisco VAMC (Site 074-002)
San Francisco, California 94121
Contact:
VA ICC
striveva@insight-trials.org

University of California San Francisco (Site 203-001)
San Francisco, California 94143
Contact:
Nashville ICC

Stanford University Hospital & Clinics (Site 203-003)
Stanford, California 94305
Contact:
Nashville ICC
strivenash@insight-trials.org

Lundquist Institute for Biomedical Innovation (Site 066-002)
Torrance, California 90502
Contact:
Washington ICC
strivewdc@insight-trials.org

Rocky Mountain Regional VA Medical Center (Site 074-010)
Aurora, Colorado 80045
Contact:
VA ICC
striveva@insight-trials.org

University of Colorado Hospital (Site 204-001)
Aurora, Colorado 80045
Contact:
Nashville ICC
strivenash@insight-trials.org

Public Health Institute at Denver Health (Site 017-004)
Denver, Colorado 80204
Contact:
Washington ICC
strivewdc@insight-trials.org

Yale University (Site 025-001)
New Haven, Connecticut 06510
Contact:
Washington ICC
strivewdc@insight-trials.org

MedStar Health Research Institute/MedStar Washington Hospital Center (Site 009-021)
Washington, District of Columbia 20010
Contact:
Washington ICC
strivewdc@insight-trials.org

Washington DC VA Medical Center (Site 009-004)
Washington, District of Columbia 20422
Contact:
Washington ICC
strivewdc@insight-trials.org

University of Florida - Gainesville (Site 201-004)
Gainesville, Florida 32610
Contact:
Washington ICC
strivewdc@insight-trials.org

Miami VA Healthcare System (Site 074-003)
Miami, Florida 33125
Contact:
VA ICC
striveva@insight-trials.org

Orlando VA Medical Center (Site 074-032)
Orlando, Florida 32827
Contact:
VA ICC
striveva@insight-trials.org

Tampa General Hospital (032-001)
Tampa, Florida 33606
Contact:
Washington ICC
strivewdc@insight-trials.org

University of Illinois at Chicago (Site 008-012)
Chicago, Illinois 60612
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Carle Foundation Hospital (Site 080-049)
Urbana, Illinois 61801
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Lutheran Medical Group (Site 301-010)
Fort Wayne, Indiana 46804
Contact:
New York ICC
striveny@insight-trials.org

The University of Kansas Hospital (Site 080-044)
Kansas City, Kansas 66160
Contact:
Hennepin ICC
strivehenn@insight-trials.org

University of Kentucky (Site 210-004)
Lexington, Kentucky 40536
Contact:
Nashville ICC
strivenash@insight-trials.org

NIH Clinical Center (Site 080-043)
Bethesda, Maryland 20892
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Massachusetts General Hospital (202-002)
Boston, Massachusetts 02114
Contact:
Nashville ICC
strivenash@insight-trials.org

Beth Israel Deaconess Medical Center (Site 202-001)
Boston, Massachusetts 02215
Contact:
Nashville ICC
strivenash@insight-trials.org

Baystate Medical Center (Site 201-001)
Springfield, Massachusetts 01199
Contact:
Nashville ICC
strivenash@insight-trials.org

UMass Chan Medical School (Site 080-007)
Worcester, Massachusetts 01655
Contact:
Washington ICC

VA Ann Arbor Healthcare System (Site 074-028)
Ann Arbor, Michigan 48105
Contact:
VA ICC
striveva@insight-trials.org

Henry Ford Health System (Site 014-001)
Detroit, Michigan 48202
Contact:
Washington ICC

Sinai-Grace Hospital (Site 205-005)
Detroit, Michigan 48235
Contact:
Nashville ICC
strivenash@insight-trials.org

Hennepin Healthcare Research Institute (Site 027-001)
Minneapolis, Minnesota 55415
Contact:
Hennepin ICC

M Health Fairview University of Minnesota Medical Center (Site 112-001)
Minneapolis, Minnesota 55455
Contact:
Hennepin ICC
strivehenn@insight-trials.org

University of Minnesota
Minneapolis, Minnesota 55455
Contact:
Rebecca Schoenecker
sitereg@insight-trials.org

Mayo Clinic (Site 054-001)
Rochester, Minnesota 55905
Contact:
Hennepin ICC
strivehenn@insight-trials.org

University of Mississippi Medical Center (Site 202-005)
Jackson, Mississippi 39216
Contact:
Nashville ICC
strivenash@insight-trials.org

Washington University School of Medicine (Site 003-001)
Saint Louis, Missouri 63110
Contact:
Washington ICC

University of Nebraska Medical Center (Site 080-045)
Omaha, Nebraska 68198
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Dartmouth-Hitchcock Medical Center (301-024)
Lebanon, New Hampshire 03756
Contact:
New York ICC
striveny@insight-trials.org

Cooper University Hospital (Site 019-001)
Camden, New Jersey 08103
Contact:
Washington ICC
strivewdc@insight-trials.org

Hackensack Meridian Health (Site 301-030)
Hackensack, New Jersey 07601
Contact:
New York ICC
striveny@insight-trials.org

New Jersey Medical School Clinical Research Center (028-001)
Newark, New Jersey 07103
Contact:
Washington ICC
strivewdc@insight-trials.org

University of New Mexico Hospital (Site 213-008)
Albuquerque, New Mexico 87106
Contact:
Nashville ICC
strivenash@insight-trials.org

CHRISTUS - St. Vincent (Site 080-051)
Santa Fe, New Mexico 87505
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Lincoln Medical Center (Site 003-016)
Bronx, New York 10451
Contact:
Washington ICC
strivewdc@insight-trials.org

Montefiore Medical Center - Moses Hospital (Site 206-001)
Bronx, New York 10467
Contact:
Nashville ICC
strivenash@insight-trials.org

Montefiore Medical Center - Weiler campus (Site 206-003)
Bronx, New York 10467
Contact:
Nashville ICC
strivenash@insight-trials.org

James J. Peters VAMC (Site 023-003)
Bronx, New York 10468
Contact:
VA ICC
striveva@insight-trials.org

NYU Brooklyn (301-033)
Brooklyn, New York 11220
Contact:
New York ICC
striveny@insight-trials.org

Mount Sinai Queens (Site 081-105)
Long Island City, New York 11102
Contact:
New York ICC

NYU Long Island (301-034)
Mineola, New York 11501
Contact:
New York ICC
striveny@insight-trials.org

New York University Tisch Hospital (Site 301-013)
New York, New York 10016
Contact:
New York ICC
striveny@insight-trials.org

Mount Sinai Medical Center (Site 301-012)
New York, New York 10029
Contact:
New York ICC
striveny@insight-trials.org

NYC Health + Hospital Harlem (Site 003-003)
New York, New York 10037
Contact:
Washington ICC
strivewdc@insight-trials.org

Weill Cornell Clinical Research Unit (065-001)
New York, New York 10065
Contact:
Washington ICC
strivewdc@insight-trials.org

St. Lawrence Health System (Site 301-029)
Potsdam, New York 13676
Contact:
New York ICC
striveny@insight-trials.org

Duke University Hospital (Site 301-006)
Durham, North Carolina 27710
Contact:
New York ICC
striveny@insight-trials.org

Wake Forest Baptist Health (Site 210-001)
Winston-Salem, North Carolina 27157
Contact:
Nashville ICC
strivenash@insight-trials.org

University of Cincinnati Medical Center (Site 207-003)
Cincinnati, Ohio 45219
Contact:
Nashville ICC
strivenash@insight-trials.org

Cleveland Clinic Foundation (Site 207-001)
Cleveland, Ohio 44195
Contact:
Nashville ICC
strivenash@insight-trials.org

Ohio State University Wexner Medical Center (Site 207-004)
Columbus, Ohio 43210
Contact:
Nashville ICC
strivenash@insight-trials.org

Portland VA Health Care System (074-024)
Portland, Oregon 97239
Contact:
VA ICC
striveva@insight-trials.org

Penn State Health Milton S. Hershey Medical Center (Site 209-002)
Hershey, Pennsylvania 17033
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Rhode Island Hospital (Site 080-036)
Providence, Rhode Island 02903
Contact:
Hennepin ICC
strivehenn@insight-trials.org

The Miriam Hospital (Site 080-039)
Providence, Rhode Island 02906
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Kent County Memorial Hospital (080-048)
Warwick, Rhode Island 02886
Contact:
Hennepin ICC
strivehen@insight-trials.org

Ralph H. Johnson VA Medical Center (Site 074-015)
Charleston, South Carolina 29401
Contact:
VA ICC
striveva@insight-trials.org

Medical University of South Carolina (Site 210-002)
Charleston, South Carolina 29425
Contact:
Nashville ICC
strivenash@insight-trials.org

Monument Health Rapid City Hospital (Site 213-005)
Rapid City, South Dakota 57701
Contact:
Nashville ICC
strivenash@insight-trials.org

Vanderbilt University Medical Center (Site 212-001)
Nashville, Tennessee 37212
Contact:
Nashville ICC

Hendrick Medical Center (Site 080-014)
Abilene, Texas 79601
Contact:
Hennepin ICC

CHRISTUS Spohn Shoreline Hospital (Site 080-001)
Corpus Christi, Texas 78405
Contact:
Hennepin ICC
strivehenn@insight-trials.org

Baylor, Scott and White Health (301-003)
Dallas, Texas 75246
Contact:
New York ICC
striveny@insight-trials.org

Parkland Health and Hospital Systems (Site 084-002)
Dallas, Texas 75390
Contact:
Washington ICC
strivewdc@insight-trials.org

UT Southwestern Medical Center (Site 084-001)
Dallas, Texas 75390
Contact:
Washington ICC
strivewdc@insight-trials.org

Houston Methodist Hospital (Site 301-028)
Houston, Texas 77030
Contact:
Hennepin ICC
strivehenn@insight-trials.org

MEDVAMC (Site 074-006)
Houston, Texas 77030
Contact:
VA ICC
striveva@insight-trials.org

University of Texas Health Science Center (Site 203-006)
Houston, Texas 77030
Contact:
Nashville ICC
strivenash@insight-trials.org

CHRISTUS Good Shepherd Medical Center (Site 080-031)
Longview, Texas 75601
Contact:
Hennepin ICC
strivehenn@insight-trials.org

UT Health San Antonio (Site 009-022)
San Antonio, Texas 78229
Contact:
Washington ICC
strivewdc@insight-trials.org

Intermountain Medical Center (Site 211-001)
Murray, Utah 84107
Contact:
Nashville ICC
strivenash@insight-trials.org

University of Utah Health (Site 211-002)
Salt Lake City, Utah 84108
Contact:
Nashville ICC
strivenash@insight-trials.org

University of Virginia Health System, University Hospital (Site 210-003)
Charlottesville, Virginia 22908
Contact:
Nashville ICC
strivenash@insight-trials.org

Salem VA Medical Center (Site 074-014)
Salem, Virginia 24153
Contact:
VA ICC

Harborview Medical Center (208-001)
Seattle, Washington 98104
Contact:
Nashville ICC
strivenash@insight-trials.org

Providence (Sacred Heart) (Site 213-004)
Spokane, Washington 99204
Contact:
Nashville ICC
strivenash@insight-trials.org

West Virginia University Medicine
Morgantown, West Virginia 26506
Contact:
New York ICC
striveny@insight-trials.org

William S. Middleton Memorial Veterans Hospital (074-030)
Madison, Wisconsin 53705
Contact:
Veterans Affairs ICC
striveva@insight-trials.org

Froedtert Memorial Lutheran Hospital (052-001)
Milwaukee, Wisconsin 53226
Contact:
Washington ICC
strivewdc@insight-trials.org

VA Caribbean Health Care (074-033)
San Juan, Puerto Rico 00921-3201
Contact:
Veterans Affairs ICC
striveva@insight-trials.org

More Details

NCT ID
NCT05605093
Status
Recruiting
Sponsor
University of Minnesota

Study Contact

Cavan Reilly, PhD
612-624-9644
cavanr@biostat.umn.edu